Is SYRE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SYRE. It does not provide personalized investment advice.

SYRE (Spyre Therapeutics, Inc. Common Stock) Stock Analysis - Financials

Spyre Therapeutics, Inc. Common Stock (SYRE) is a publicly traded Healthcare sector company. As of September 3, 2026, SYRE trades at $87.26 with a market cap of $7.68B and a P/E ratio of 0.00. SYRE moved +0.23% today. Year to date, SYRE is +185.32%; over the trailing twelve months it is +413.54%. Its 52-week range spans $10.91 to $110.18. Analyst consensus is strong buy with an average price target of $119.45. Rallies surfaces SYRE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are SYRE's key financials?

SYRE financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. SYRE recently traded at $87.26. Market cap is $7.68B. P/E ratio is 0.00. Revenue is $0.

SYRE Key Metrics

Key financial metrics for SYRE
Metric	Value
Price	$87.26
Market Cap	$7.68B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$110.18
52-Week Low	$10.91
Volume	718.57K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-155.20M
Gross Margin	0.00%

SYRE Analyst Consensus

14 analysts cover SYRE: 0 strong buy, 13 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $119.45.

Common questions about SYRE

What are SYRE's key financials?: SYRE financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. SYRE recently traded at $87.26. Market cap is $7.68B. P/E ratio is 0.00. Revenue is $0.
Is SYRE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SYRE. It does not provide personalized investment advice.